Independent health agency continues to attract industry’s brightest minds; fortifies teams companywide as part of commitment to delivering industry-leading innovation,...
Manufacturing of instruments, consumables and reagents for cell and protein analysisConsolidation of existing sites and functions in Ann ArborOverall investment...
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address...
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte...
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Helping pharmacies deliver smart patient messaging while giving time back to pharmacists WOBURN, Mass., June 5, 2024 /PRNewswire/ -- MedAdvisor Solutions,...
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON,...
TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a...
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall...
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer...
Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) -- The EAACI...
If approved, IXCHIQ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV)Decision on EU marketing...
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License...
Throughout June close to 50 communities will be gathering across Canada to raise funds for type 1 diabetes researchTORONTO, May...
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE...
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with...
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for...